Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study
Maternal And Neonatal Outcome of Pregnant Patients With COVID-19
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
İ̇stanbul
-
Istanbul, İ̇stanbul, Turkey, 34000
- Pinar Yalcin Bahat
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- from covid 19 positive mothers
- newborn mothers had not other condition or illness
Exclusion Criteria:
- from covid 19 negative mothers
- childs
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of apgar status of newborns from covid 19 positive mothers
Time Frame: 2 months
|
The Apgar score is looked after at 1 and 5 minutes after birth, if the baby's Apgar score is lower than 7, it is repeated every 5 minutes until 20 minutes. Parameters examined in Apgar score Muscle tone, Heart rate, Reflexes, Skin color, Respiration. In the Apgar score, the baby is evaluated and scores are collected. 7 - 10: The baby is normal. 4 - 6: They usually recover with respiratory support. 0 - 3: Urgent intervention and resuscitation is needed. The low Apgar score in the 1st minute usually returns to normal in the 5th minute with support. Despite the intervention, the Apgar scores of 5 and less at 5 and 10 minutes are associated with an increased risk of mortality and cerebral palsy. |
2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- covid19pregnancynewborn
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.